系统性红斑狼疮的药物治疗进展。
Advances in drug therapy for systemic lupus erythematosus.
机构信息
Division of Rheumatology, Cedars-Sinai Medical Center, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA.
出版信息
BMC Med. 2010 Nov 29;8:77. doi: 10.1186/1741-7015-8-77.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are currently in development. This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted.
摘要
系统性红斑狼疮（SLE）是一种自身免疫性疾病，影响美国 50 万人。自 1958 年以来，美国尚未批准新的 SLE 药物。然而，2005 年食品和药物管理局发布的一份指导文件为研究人员提供了路线图，催生了许多正在进行的临床试验。其中，针对可溶性 B 淋巴细胞刺激物的单克隆抗体 Belimumab 在两项大型试验中达到了主要终点，可能很快就会获得 FDA 批准。其他针对各种作用机制的有前途的药物目前正在开发中。这篇迷你评论强调了 SLE 正在研究的最新疗法，并概述了正在针对的具体途径。
相似文献
1
Advances in drug therapy for systemic lupus erythematosus.系统性红斑狼疮的药物治疗进展。
BMC Med. 2010 Nov 29;8:77. doi: 10.1186/1741-7015-8-77.
2
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.贝利尤单抗治疗系统性红斑狼疮患者的疗效和安全性：一项随机、安慰剂对照、3 期临床试验。
Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.
3
Belimumab and the clinical data.贝利木单抗和临床数据。
Curr Rheumatol Rep. 2012 Aug;14(4):310-7. doi: 10.1007/s11926-012-0264-4.
4
Belimumab: review of use in systemic lupus erythematosus.贝利尤单抗：治疗系统性红斑狼疮的应用评价。
Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Epub 2012 Mar 30.
5
Targeting BLyS in systemic lupus erythematosus.系统性红斑狼疮中针对B淋巴细胞刺激因子的研究
Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):91-6. doi: 10.2174/187221312800166831.
6
Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.贝利尤单抗治疗系统性红斑狼疮的疗效、药代动力学及药效学特征
Expert Opin Drug Metab Toxicol. 2015;11(10):1635-45. doi: 10.1517/17425255.2015.1077808. Epub 2015 Sep 1.
7
Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.贝利尤单抗：抗B淋巴细胞刺激因子人源单克隆抗体、抗B淋巴细胞刺激因子单克隆抗体、BmAb、抗B淋巴细胞刺激因子人源单克隆抗体
Drugs R D. 2008;9(3):197-202. doi: 10.2165/00126839-200809030-00008.
8
Belimumab: a guide to its use in systemic lupus erythematosus.贝利尤单抗：在系统性红斑狼疮中的应用指南。
BioDrugs. 2012 Jun 1;26(3):195-9. doi: 10.2165/11209060-000000000-00000.
9
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.打破系统性红斑狼疮的僵局：贝利尤单抗，一种有前途的新疗法。
Lupus. 2013 Apr;22(4):361-71. doi: 10.1177/0961203312471575.
10
Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.靶向B细胞疗法在成人及儿童系统性红斑狼疮治疗中的应用
Lupus. 2016 Sep;25(10):1086-96. doi: 10.1177/0961203316652491.
引用本文的文献
1
Regulation of cGAS-STING Pathway - Implications for Systemic Lupus Erythematosus.cGAS-STING通路的调控——对系统性红斑狼疮的影响
Rheumatol Immunol Res. 2021 Dec 15;2(3):173-184. doi: 10.2478/rir-2021-0023. eCollection 2021 Sep.
2
Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside.Ⅰ型干扰素在系统性红斑狼疮中的作用：从基础到临床。
Int J Mol Sci. 2022 Feb 24;23(5):2505. doi: 10.3390/ijms23052505.
3
Metabolic Targets for Treatment of Autoimmune Diseases.自身免疫性疾病治疗的代谢靶点
Immunometabolism. 2020;2(2). doi: 10.20900/immunometab20200012. Epub 2020 Mar 31.
4
Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study.接受羟氯喹治疗患者的视网膜毒性：一项横断面研究。
Med Hypothesis Discov Innov Ophthalmol. 2016 Summer;5(2):41-46.
5
Nonsteroidal Anti-Inflammatory Drugs Quickly Resolve Symptoms Associated with EBV-Induced Infectious Mononucleosis in Patients with Atopic Predispositions.非甾体抗炎药可迅速缓解特应性易感性患者中与EB病毒诱导的传染性单核细胞增多症相关的症状。
Am J Case Rep. 2016 Feb 14;17:84-8. doi: 10.12659/ajcr.895399.
6
Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus.外周血淋巴细胞上P-糖蛋白的持续表达及功能可识别系统性红斑狼疮患者的皮质类固醇耐药性。
Clin Rheumatol. 2016 Feb;35(2):341-9. doi: 10.1007/s10067-015-3079-7. Epub 2015 Sep 29.
7
Resveratrol possesses protective effects in a pristane-induced lupus mouse model.白藜芦醇在 pristane 诱导的狼疮小鼠模型中具有保护作用。
PLoS One. 2014 Dec 11;9(12):e114792. doi: 10.1371/journal.pone.0114792. eCollection 2014.
8
Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.T淋巴细胞中表达的延迟整流钾通道（Kv1.3）的生理意义及其在慢性肾脏病中的病理意义。
J Physiol Sci. 2015 Jan;65(1):25-35. doi: 10.1007/s12576-014-0331-x. Epub 2014 Aug 6.
9
Guidelines on the use of extracorporeal photopheresis.体外光化学疗法使用指南。
J Eur Acad Dermatol Venereol. 2014 Jan;28 Suppl 1(Suppl 1):1-37. doi: 10.1111/jdv.12311.
10
Aicardi-Goutières syndrome: a model disease for systemic autoimmunity.Aicardi-Goutières 综合征：全身性自身免疫的典范疾病。
Clin Exp Immunol. 2014 Jan;175(1):17-24. doi: 10.1111/cei.12160.
本文引用的文献
1
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.利妥昔单抗治疗活动性增殖性狼疮性肾炎患者的疗效和安全性：利妥昔单抗狼疮性肾炎评估研究
Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.
2
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.阿巴西普治疗非危及生命的系统性红斑狼疮患者的疗效和安全性：一项为期12个月、多中心、探索性、IIb期、随机、双盲、安慰剂对照试验的结果。
Arthritis Rheum. 2010 Oct;62(10):3077-87. doi: 10.1002/art.27601.
3
Topical calcineurin inhibitors in systemic lupus erythematosus.局部钙调磷酸酶抑制剂治疗系统性红斑狼疮。
Ther Clin Risk Manag. 2010 Apr 15;6:95-101. doi: 10.2147/tcrm.s3193.
4
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.托珠单抗治疗系统性红斑狼疮：来自一项开放标签I期剂量递增研究的安全性、初步疗效及对循环浆细胞影响的数据
Arthritis Rheum. 2010 Feb;62(2):542-52. doi: 10.1002/art.27221.
5
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.利妥昔单抗治疗中度至重度活动性系统性红斑狼疮的疗效和安全性：利妥昔单抗治疗系统性红斑狼疮的随机、双盲、II/III期试验
Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.
6
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.英夫利昔单抗治疗系统性红斑狼疮患者的不良事件及肿瘤坏死因子-α阻断疗效：13例患者的长期随访
Rheumatology (Oxford). 2009 Nov;48(11):1451-4. doi: 10.1093/rheumatology/kep270. Epub 2009 Sep 11.
7
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.贝利尤单抗治疗活动性系统性红斑狼疮患者的II期随机双盲安慰剂对照剂量范围研究。
Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.
8
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.霉酚酸酯与环磷酰胺用于狼疮性肾炎诱导治疗的比较
J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15.
9
Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.甲氨蝶呤对系统性红斑狼疮的激素节省作用：一项双盲、随机、安慰剂对照试验。
Arthritis Rheum. 2008 Dec 15;59(12):1796-804. doi: 10.1002/art.24068.
10
Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.阿贝替莫钠治疗系统性红斑狼疮肾活动：一项随机对照III期试验的结果
Arthritis Rheum. 2008 Aug;58(8):2470-80. doi: 10.1002/art.23673.
Zotero 插件